01Approach to the Critical Patient/attcp58

Immediate priorities

›Airway and oxygenation threats

›Hypoxemia requiring escalation

›SpO2 <90% on room air

›Increasing O2 requirement from baseline

›Ventilatory failure

›Rising PaCO2 with altered mental status

›Respiratory fatigue and accessory muscle use

›If SpO2 <88% on high-flow, initiate NIV (BiPAP) as bridge

›Intubation if NIV fails or mental status declines

›Lung-protective ventilation strategy for CF physiology

›Massive hemoptysis

›Volume threshold >240 mL defines massive hemoptysis

›Lifetime incidence ~4.1% in CF patients

›ICU admission required

›Immediate actions

›Position patient with bleeding lung dependent

›Hold all airway clearance therapies

›Bronchial artery embolization planning via IR

›Pneumothorax recognition

›Annual incidence ~0.64% in CF; higher in advanced disease

›Acute pleuritic chest pain with dyspnea

›Absent breath sounds on affected side

›Urgent chest decompression if tension physiology

›Chest tube drainage for confirmed pneumothorax

›Avoid pleurodesis if lung transplant candidacy is possible

Monitoring and targets

›Monitoring bundle

02History/hx73

Symptom characterization

›Cardinal respiratory symptoms

›Cough frequency and severity change from baseline

›Nocturnal cough onset 17 days before treatment on average

›Earliest digital biomarker of impending exacerbation

›Sputum volume increase

›Color change (clear to yellow or green)

›Consistency change (thicker, more viscous)

›Dyspnea at rest or with exertion

›Comparison to patient's functional baseline

›Exercise tolerance decline

Systemic symptoms

›Constitutional features

›Fever above 38°C

›Chills and rigors

›Antipyretic masking effect

›Weight loss and anorexia

›Comparison to most recent clinic weight

›Caloric intake reduction estimate

›Fatigue and malaise

›School or work absenteeism

›Activity level reduction per caregiver

Alarm symptoms

›Hemoptysis

›Volume quantification (teaspoons, cups)

›<5 mL: minor, continue management

›>240 mL: massive, emergency

›Frequency and duration

03Physical Exam/exam45

Vital signs

›Respiratory parameters

›Tachypnea rate and trend

›Increased work of breathing

›Accessory muscle use

›SpO2 compared to patient's documented baseline

›≥10% decline from baseline supports Fuchs criteria

›Fever above 38°C

›One of the Fuchs diagnostic criteria

Pulmonary examination

›Auscultation findings

›New or increased crackles

›Localized vs. diffuse

›Change from prior exam if documented

›Rhonchi and wheeze

›Post-airway clearance change in character

›Decreased air entry

›Lobar collapse or mucus plugging

›Absent breath sounds: pneumothorax

›Work of breathing

›Nasal flaring

›Intercostal retractions

›Paradoxical breathing pattern

Systemic and nutritional assessment

›Nutritional status

›Weight compared to most recent clinic weight

›>5% loss indicates significant catabolism

›Temporal wasting and muscle mass loss

04Differential Diagnosis/ddx51

Pulmonary complications of CF

›Pneumothorax (J93.1x)

›Annual incidence ~0.64% in CF

›More common in advanced disease

›Acute pleuritic pain and dyspnea

›Differentiating features

›Absent breath sounds on affected side

›CXR or point-of-care ultrasound diagnostic

›Massive hemoptysis (R04.2)

›Volume >240 mL defines massive

›Lifetime incidence ~4.1% in CF

›Differentiating features

›Bright red blood from airways

›Hemodynamic compromise in severe cases

›Allergic bronchopulmonary aspergillosis (ABPA) (J17.2)

›Therapy-resistant bronchospasm and mucus plugging

›Elevated total IgE >1000 IU/mL

›Peripheral eosinophilia

›Differentiating features

›Central bronchiectasis on HRCT

›Aspergillus-specific IgE positive

Infectious mimics

›Non-tuberculous mycobacteria infection (A31.0)

›Insidious decline not responding to standard anti-pseudomonal therapy

›M. abscessus most clinically important

›Requires specialized culture protocol

›Differentiating features

›AFB smear and culture from sputum

05Laboratory Tests/lt45

Microbiologic studies

›Sputum culture and sensitivity

›CF-specific processing required

›Selective media for Pseudomonas aeruginosa

›Selective media for Burkholderia cepacia complex

›Stenotrophomonas maltophilia culture

›Obtain before starting IV antibiotics

›Guides antibiotic de-escalation or adjustment

›IDSA/ASM 2024 guideline recommendation

›NTM culture

›Routine addition for patients >15 years presenting with exacerbation

›AFB smear plus liquid and solid culture media

›Results take weeks; initiate empiric CF therapy while pending

›Respiratory viral panel

›Multiplex PCR if viral trigger suspected

›Influenza, RSV, SARS-CoV-2, rhinovirus

›Viral co-infection identified in ~22% of exacerbations

Inflammatory biomarkers

›C-reactive protein (CRP)

›Most validated blood biomarker for CF exacerbation

›Threshold >9.5 mg/L discriminates exacerbation from stable state

›Sensitivity 76%, specificity 73%

›Useful for monitoring treatment response

›Serial CRP over 3-5 days

›CBC with differential

›Leukocytosis suggests bacterial exacerbation

›Eosinophilia raises ABPA concern

›Anemia from chronic disease common

06Diagnostic Tests/dt70

Scoring Systems

›Fuchs criteria for CF pulmonary exacerbation diagnosis

›Most widely used clinical and research framework

›Requires ≥4 of 12 signs and symptoms

›No universally accepted alternative definition exists

›12 Fuchs criteria signs and symptoms

›Increased cough frequency

›Increased sputum production

›Change in sputum color or character

›Increased dyspnea

›Fever above 38°C

›Decreased appetite or weight loss

›Fatigue or malaise

›Decreased exercise tolerance

›Decreased FEV1 ≥10% from baseline

›Decreased SpO2 ≥10% from baseline

›New radiographic changes

›New or changed auscultatory findings

›Spirometry severity assessment

›FEV1 decline from patient's personal best

›Mild: FEV1 >70% predicted

›Moderate: FEV1 40-70% predicted

›Severe: FEV1 <40% predicted

›FEV1/FVC ratio for obstruction pattern

›Obstructive pattern typical of CF

›CFQ-R (Cystic Fibrosis Questionnaire-Revised)

›Validated patient-reported outcome measure

›Respiratory symptom scale correlates with FEV1

07Disposition/dispo39

Admission criteria

›Indications for hospital admission

›Moderate-severe exacerbation requiring IV antibiotics

›Significant FEV1 decline ≥10% from baseline

›Systemic symptoms: fever, weight loss, fatigue

›Hypoxemia or respiratory distress

›SpO2 <92% on room air or new O2 requirement

›Tachypnea with accessory muscle use

›Failure of outpatient oral antibiotic therapy

›No improvement after 48-72 hours of oral ciprofloxacin

›Complications requiring inpatient management

›Hemoptysis requiring monitoring or intervention

›Pneumothorax

›DIOS not responding to outpatient measures

›Inability to perform adequate airway clearance at home

›Comorbidities complicating management

›CFRD requiring insulin adjustment

›Renal dysfunction requiring aminoglycoside monitoring

ICU and escalation criteria

›ICU admission triggers

›Massive hemoptysis >240 mL

›Hemodynamic instability

›Airway compromise

›Acute respiratory failure

›SpO2 <88% despite HFNC or NIV

›PaCO2 rising with altered mental status

›Tension pneumothorax or bilateral pneumothorax

08Treatment/t118

Antibiotic therapy

›IV dual antibiotic therapy for moderate-severe exacerbation

›Aminoglycoside backbone

›Tobramycin 10 mg/kg/day divided q8h or once-daily dosing

›Once-daily dosing preferred at many CF centers

›Trough target <1 mg/L; peak target 8-12 mg/L

›Antipseudomonal beta-lactam partner

›Piperacillin-tazobactam 4.5 g IV q6-8h

›Ceftazidime 2 g IV q8h

›Meropenem 1 g IV q8h for resistant organisms

›Antibiotic selection guided by most recent sputum culture

›Adjust after new culture sensitivities return

›Treatment duration

›Standard duration 10-14 days

›10 days noninferior to 14 days for patients improving by day 7-10 (RCT, n=982)

›21 days not superior to 14 days in non-responders

›Early responders: may complete 10-day course

›Non-responders: reassess culture, consider resistant pathogens

›Oral antibiotic option for mild exacerbations

›Ciprofloxacin 750 mg PO q12h for 10-14 days

›Active against Pseudomonas aeruginosa

›Trial appropriate before IV escalation in mild cases

›Trimethoprim-sulfamethoxazole for MRSA if sensitive

›1-2 DS tablets PO q12h

›MRSA-directed therapy

›Vancomycin 15-20 mg/kg IV q8-12h (AUC-guided dosing)

›Target AUC/MIC 400-600

›Trough not recommended as sole monitoring parameter

›Linezolid 600 mg PO/IV q12h as alternative

›Oral bioavailability equivalent to IV

Airway clearance

›Intensified airway clearance regimen

›High-frequency chest wall oscillation (HFCWO vest)

›Increase frequency from baseline schedule

›2-4 sessions per day during inpatient admission

›Oscillating positive expiratory pressure devices

›Acapella or Aerobika as alternatives

›Active cycle of breathing technique

›Postural drainage with percussion if tolerated

›Hold if hemoptysis present or recent

›Mucolytic adjuncts

›Dornase alfa (pulmozyme) 2.5 mg nebulized daily or BID

›Continue throughout exacerbation

›Administer before airway clearance for optimal effect

›Hypertonic saline 7% 4 mL nebulized BID

›Continue throughout exacerbation

›Pretreat with bronchodilator to prevent bronchospasm

›Bronchodilator before nebulized therapies

›Salbutamol 2.5 mg nebulized or 2-4 puffs MDI

CFTR modulator therapy

›Continue CFTR modulators throughout exacerbation

›Elexacaftor-tezacaftor-ivacaftor (Trikafta/Kaftrio)

›Do not hold during exacerbation

›Reduces exacerbation rates by ~63%

›In HEMT era, exacerbations may present more subtly

›Ivacaftor (Kalydeco) for Class III mutations

›Continue on current dosing schedule

›Monitor LFTs if hepatic concern with CFTR modulators

›Aminotransferase elevations can occur

Supportive therapies

›Supplemental oxygen

›Titrate to maintain SpO2 ≥92%

›Nasal cannula for mild hypoxemia

›HFNC for moderate-severe hypoxemia

›BiPAP/NIV for hypercapnic respiratory failure

›Start: IPAP 10-14 cmH2O, EPAP 4-6 cmH2O

›Titrate to achieve PaCO2 reduction and dyspnea relief

›Nutritional support

›High-calorie, high-protein diet during exacerbation

›120-150% of estimated energy requirements

›Dietitian consultation for all admissions

›Pancreatic enzyme replacement with every meal and snack

›Adjust dose to prevent steatorrhea

›Fat-soluble vitamins A, D, E, K continuation

›CF-specific formulations preferred

›Enteral nutrition via NG or gastrostomy if oral intake inadequate

›Overnight feeds to supplement daytime caloric intake

›Glucose management for CFRD

›Insulin dose escalation during exacerbation

›Glucose intolerance predictably worsens

›Fasting glucose target 5-8 mmol/L

›Postprandial glucose target <10 mmol/L

›Point-of-care glucose monitoring QID

›Bronchodilators

›Short-acting beta-2 agonist as needed

›Salbutamol 2.5 mg nebulized q4-6h PRN

›Ipratropium if bronchospasm component

›0.5 mg nebulized q6-8h

Complication-specific treatment

›Massive hemoptysis management

›Immediate actions

›Hold all airway clearance immediately

›Correct any coagulopathy (vitamin K, FFP if needed)

›Protect airway; position bleeding lung dependent

›Bronchial artery embolization (BAE)

›First-line definitive intervention

›Interventional radiology consultation

›Recurrence rate 20-30% at 1 year

›Avoid NSAIDS and anticoagulants

›Hold high-dose ibuprofen

›Review all antiplatelet medications

›Pneumothorax management

›Small pneumothorax (<20%): supplemental O2 and observation

›Accelerates nitrogen absorption

›Large pneumothorax or symptomatic: chest tube drainage

›Pigtail catheter or large-bore chest tube

›Avoid pleurodesis if transplant candidacy is possible

›Air leak persisting >5 days

›Thoracic surgery consultation

›DIOS management

›Gastrografin (diatrizoate) oral or enema

›100 mL orally or per rectum

›Hyperosmolar agent softens obstructing fecal mass

›Polyethylene glycol (PEG) 1-2 L orally over 2-4 hours

›Adequate hydration throughout

›Increase pancreatic enzyme dosing going forward

›Drug safety cautions

›Hold high-dose ibuprofen during IV aminoglycoside therapy

›Additive nephrotoxicity risk

›Monitor aminoglycoside levels closely

›Baseline creatinine and electrolytes before initiation

›QTc monitoring with azithromycin plus fluoroquinolone

›QTc >500 ms: reassess combination therapy

09Special Populations/sp79

Pregnancy

›CF in pregnancy considerations

›Maternal FEV1 and baseline lung function

›FEV1 <60% predicted associated with higher pregnancy complication risk

›FEV1 <40% predicted: significant maternal morbidity risk

›Exacerbation rate does not clearly increase in pregnancy

›Physiologic changes alter presentation and tolerance

›Antibiotic safety in pregnancy

›IV tobramycin: use with caution

›Crosses placenta; fetal ototoxicity and nephrotoxicity risk

›Monitor levels closely; use shortest effective course

›Benefit-risk assessment required; aminoglycosides Category D

›Beta-lactams (piperacillin-tazobactam, ceftazidime): generally safe

›Category B agents

›Preferred beta-lactam backbone in pregnancy

›Ciprofloxacin: avoid if possible in first trimester

›Cartilage toxicity concern; generally avoided

›Use only if no safer alternative for Pseudomonas

›Meropenem: Category B; use if required

›CFTR modulator safety

›Elexacaftor-tezacaftor-ivacaftor (ETI): limited pregnancy data

›Case series suggest favorable outcomes; not FDA-approved in pregnancy

›CFF guidance: discuss risk-benefit with patient and CF team

›Consider continuing if CF is severe and modulator is providing benefit

›Nutritional considerations in pregnancy

›Increased caloric requirements above already elevated CF baseline

›Target 2500-3500 kcal/day

›Dietitian involvement essential

›Folic acid supplementation

›CFRD monitoring intensified during pregnancy

›Gestational diabetes screening compounded by CFRD

Geriatric

›Geriatric CF considerations

›Aging CF population due to improved survival

›Median predicted survival now exceeds 50 years in high-income settings

›First generation of older CF adults with complex comorbidities

›Accumulation of organ complications

›CF-related liver disease and portal hypertension

›Osteoporosis and vertebral fractures

›CF-related diabetes well-established

›Antibiotic considerations in older CF patients

›Aminoglycoside nephrotoxicity risk increased

›Age-related decline in GFR requires dose adjustment

›More frequent level monitoring

›Shorter courses if renal function compromised

›Drug-drug interactions more prevalent

›Multiple chronic medications typical

›Review for QTc-prolonging agents

›Respiratory support considerations

›Lower threshold for NIV in patients with chronic hypercapnia

›Chronic domiciliary NIV common in advanced disease

›Adjust from home settings during exacerbation

›Frailty assessment guides escalation limits

›Advance directive and goals-of-care discussion

›Transplant candidacy assessment if not yet evaluated

Pediatrics

›Pediatric CF exacerbation features

›Spirometry feasible from age 6 years in cooperative children

›FEV1 decline still primary severity marker

›Younger children: clinical assessment and SpO2 monitoring

›School-age children: home spirometry monitoring programs

›FEV1 decline detectable 8 days before treatment in some studies

›Home spirometry exacerbation profiles validated in pediatric cohorts

›Antibiotic dosing in pediatrics

›Tobramycin: 10 mg/kg/day IV divided q8h or once-daily

›Higher weight-based doses often required in children

›Faster drug clearance in pediatric patients

›Drug level monitoring mandatory

›Piperacillin-tazobactam: 300-400 mg/kg/day divided q6-8h (max 16 g/day piperacillin component)

›Meropenem: 60-120 mg/kg/day divided q8h (max 6 g/day)

›Ciprofloxacin: 20-30 mg/kg/day PO divided q12h for mild exacerbations

›Airway clearance in pediatrics

›Age-appropriate devices

›HFCWO vest from toddler age with appropriate sizes

›PEP mask from approximately age 4

›Acapella from age 4-6 depending on coordination

›Parental and caregiver training essential

›Radiation minimization

›Lung ultrasound preferred over CXR for consolidation when feasible

›AUROC 0.966 vs. 0.483 for CXR in CF patients

›HRCT reserved for complex presentations

›Low-dose protocols to minimize cumulative radiation

10Background/b77

Epidemiology

›Prevalence and demographics

›Approximately 105,000 individuals with CF worldwide

›~30,000 in the United States

›Predominantly affects people of Northern European descent

›Median predicted survival

›Exceeds 50 years in high-income countries in the HEMT era

›Historical median survival was <10 years before modern therapies

›Exacerbation burden

›Average 1-3 exacerbations per year in moderate-severe disease

›Frequency increases with advancing lung disease

›Each exacerbation associated with residual FEV1 decline

›~44% of patients do not return to baseline FEV1 at 60 days post-treatment

›Underscores importance of early treatment and prevention

›HEMT era impact

›ETI reduces exacerbation rates ~63%

›Exacerbations may present more subtly

›Provider practices adapting (Toporek et al., ATS 2025)

Pathophysiology

›CFTR mutation and ion transport defect

›CFTR gene on chromosome 7q31.2

›F508del mutation most common (~85% of CF patients carry at least one allele)

›Over 2000 CFTR variants identified; classes I-VI

›Defective chloride and bicarbonate transport

›Thick, dehydrated airway surface liquid

›Impaired mucociliary clearance

›Mucus plugging and bacterial colonization

›Infectious cycle

›Early colonization with Staphylococcus aureus and Haemophilus influenzae

›Transitions to Pseudomonas aeruginosa in older patients

›Pseudomonas biofilm formation prevents eradication

›Chronic inflammation

›Neutrophilic airway inflammation disproportionate to bacterial burden

›Elastase and proteases damage airway architecture

›Progressive bronchiectasis develops

›Exacerbation triggers

›Viral respiratory infection

›Identified in ~22% of exacerbations

›Rhinovirus, influenza, RSV most common

›New or resistant bacterial acquisition

›New Pseudomonas strain or MRSA

›NTM superinfection

›Reduced mucociliary clearance

›Dehydration

›Non-adherence to airway clearance

›Systemic stress

›Surgical procedures

›Pregnancy

Therapeutic Considerations

›Antibiotic selection rationale

›Dual therapy targets Pseudomonas aeruginosa

›Synergy between aminoglycoside and beta-lactam

›Reduces emergence of resistance

›Culture-directed adjustment

›Susceptibility testing essential for appropriate coverage

›Burkholderia cepacia: intrinsically resistant to many agents

›NTM requires species-specific multi-drug regimen

›Duration evidence base

›RCT (n=982): 10 days noninferior to 14 days in responders

›21 days not superior to 14 days in non-responders

›Cochrane review supports IV antibiotics over inhaled alone for moderate-severe exacerbations

›CFTR modulator impact on management

›ETI reduces exacerbation frequency dramatically

›Patients on ETI who exacerbate may have more subtle presentations

›Providers broadening assessment criteria in HEMT era

›ETI does not eliminate exacerbation risk

›Patients with advanced established bronchiectasis still exacerbate

›Continue standard exacerbation treatment alongside modulators

›Lung transplantation considerations

›Referral threshold: FEV1 declining to 30% predicted or rapid decline

›CFF consensus guidelines for advanced CF lung disease

›Early referral allows adequate evaluation time

›Avoid pleurodesis in transplant candidates

›Pleural symphysis increases surgical complexity

›Chest tube drainage without pleurodesis for pneumothorax

›Inhaled antibiotic prophylaxis

›Inhaled tobramycin 300 mg BID alternating months

›Reduce exacerbation frequency in Pseudomonas-colonized patients

›Aztreonam for inhalation 75 mg TID alternating months

›Alternative to inhaled tobramycin

11Patient Discharge Instructions/pdi48

copy discharge instructions

›Understanding your CF exacerbation

›You have been treated for a worsening of your cystic fibrosis lung condition

›This is called a pulmonary exacerbation

›Your lungs became more congested and infected, requiring stronger treatment

›Recovery takes time

›Symptoms typically improve within 7-10 days of starting antibiotics

›Your lung function (FEV1) may not return to your usual level right away

›Some patients remain below their best lung function for weeks to months

›Your antibiotic treatment at home

›Take all antibiotics exactly as prescribed and for the full course

›Do not stop early even if you feel better

›Contact your CF clinic if you experience side effects

›IV antibiotics at home require careful nursing follow-up

›Keep all scheduled nursing visits for line care and blood tests

›Report any redness, swelling, or pain at your IV site

›Airway clearance is critical

›Perform airway clearance at least twice daily, more if advised

›Use your vest, PEP device, or prescribed method consistently

›Do not skip sessions even if you feel tired

›Take your nebulized medications in the correct order

›Bronchodilator first, then dornase alfa or hypertonic saline, then airway clearance

›Continue all your usual CF medications

›Do not stop your CFTR modulator (Trikafta/Kaftrio or other)

›This medication reduces your risk of future exacerbations

›Take your pancreatic enzymes with every meal and snack

›Continue your vitamins as prescribed

›Nutrition and hydration

12References/r52

Guidelines and key sources

›Flume PA, Mogayzel PJ, Robinson KA, et al.

›Cystic Fibrosis Pulmonary Guidelines: Treatment of Pulmonary Exacerbations

›American Journal of Respiratory and Critical Care Medicine, 2009

›Primary guidelines for exacerbation management

›Flume PA, Mogayzel PJ, Robinson KA, et al.

›Cystic Fibrosis Pulmonary Guidelines

›American Journal of Respiratory and Critical Care Medicine, 2010

›Chronic medications management

›Kapnadak SG, Dimango E, Hadjiliadis D, et al.

›Cystic Fibrosis Foundation Consensus Guidelines for the Care of Individuals With Advanced Cystic Fibrosis Lung Disease

›Journal of Cystic Fibrosis, 2020

›Advanced disease and transplant referral guidance

›King CS, Brown AW, Aryal S, Ahmad K, Donaldson S.

›Critical Care of the Adult Patient With Cystic Fibrosis

›Chest, 2019

›ICU management and complications

Landmark trials and systematic reviews

›Hurley MN, Smith S, Flume P, Jahnke N, Prayle AP.

›Intravenous Antibiotics for Pulmonary Exacerbations in People With Cystic Fibrosis

›Cochrane Database of Systematic Reviews, 2025

›Duration evidence: 10 days noninferior to 14 days in responders

›Smith S, Rowbotham NJ, Charbek E.

›Inhaled Antibiotics for Pulmonary Exacerbations in Cystic Fibrosis

›Cochrane Database of Systematic Reviews, 2022

›Inhaled vs. IV antibiotic evidence base

›Middleton PG, Mall MA, Drevinek P, et al.

›Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis With a Single Phe508del Allele

Evidence & Review